Investigation of possible epistatic interactions between GRIA2 and GRIA4 variants on clinical outcomes in patients with major depressive disorder

Journal of International Medical Research

Volumn 41, Issue 3, 2013, Pages 809-815

  Chiesa, Alberto ^a,b   Lia, Loredana ^a   Lia, Claudia ^a   Lee, Soo Jung ^c   Han, Changsu ^d   Patkar, Ashwin A ^e   Pae, Chi Un ^c,e   Serretti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c The Catholic University of Korea   (South Korea)

^d Korea University   (South Korea)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

AMPA 2 (GRIA2); AMPA 4 (GRIA4); epistasis; Glutamate receptor; glutamate receptor; glutamatergic; ionotropic; major depression; single nucleotide polymorphism

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; MIRTAZAPINE; PAROXETINE; VENLAFAXINE;

ADULT; ARTICLE; DRUG RESPONSE; EPISTASIS; FEMALE; GENE; GENE INTERACTION; GRIA2 GENE; GRIA4 GENE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH KOREA;

AMPA 2 (GRIA2); AMPA 4 (GRIA4); EPISTASIS; GLUTAMATE RECEPTOR; GLUTAMATERGIC; IONOTROPIC; MAJOR DEPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTIDEPRESSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DEPRESSIVE DISORDER, MAJOR; EPISTASIS, GENETIC; FEMALE; GENE FREQUENCY; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, AMPA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84887327024     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060513477295     Document Type: Article

References (26)

1. Kessler RC,Berglund P,Demler O,et al.The epidemiology of major depressive disorder: results from the National Comorbidiy Survey Replication (NCS-R).JAMA. 2003;289:3095-3105.
2. Belmaker RH,Agam G.Major depressive disorder.N Engl J Med. 2008;358:55-68.
3. Kato M.Possibility of a pharmacogenetic approach for prediction and personalized medication in major depressive disorder treatment.Nihon Shinkei Seishin Yakurigaku Zasshi. 2010;30:83-92.
4. Malhotra AK,Murphy GM Jr,Kennedy JL.Pharmacogenetics of psychotropic drug response.Am J Psychiatry. 2004;161:780-796.
5. Maeng S,Zarate CA Jr.The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects.Curr Psychiatry Rep. 2007;9:467-474.
6. Carlborg O,Haley CS.Epistasis: too often neglected in complex trait studies?.Nat Rev Genet. 2004;5:618-625.
7. Segurado R,Bellgrove MA,Manconi F,et al.Epistasis between neurochemical gene polymorphisms and risk for ADHD.Eur J Hum Genet. 2011;19:577-582.
8. Kokras N,Antoniou K,Polissidis A,et al.Antidepressants induce regionally discrete, sex-dependent changes in brain's glutamate content.Neurosci Lett. 2009;464:98-102.
9. Fabbri C, Drago A and Serretti A. Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR*D. Eur Neuropsychopharmacol 2012; epub ahead of print 9 August 2012.
10. Lane HY,Tsai GE,Lin E.Assessing gene-gene interactions in pharmacogenomics.Mol Diagn Ther. 2012;16:15-27.
11. Pae CU,Drago A,Patkar AA,et al.Epistasis between a set of variations located in the TAAR6 and HSP-70 genes toward schizophrenia and response to antipsychotic treatment.Eur Neuropsychopharmacol. 2009;19:806-811.
12. Pae CU,Drago A,Forlani M,et al.Investigation of an epistastic effect between a set of TAAR6 and HSP-70 gene variations and major mood disorders.Am J Med Genet B Neuropsychiatr Genet. 2010;153B:680-683.
13. Chiesa A,Crisafulli C,Porcelli S,et al.Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder.Eur Arch Psychiatry Clin Neurosci. 2012;262:305-311.
14. Diagnostic and Statistical Manual of Mental Disorders. 4th edition (DSM-IV). Washington DC: American Psychiatric Press, 2004.Washington DC: American Psychiatric Press; 2004:.
15. Sheehan DV,Lecrubier Y,Sheehan KH,et al.The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.J Clin Psychiatry. 1998;59:22-33.
16. Montgomery S,Asberg M.A new depression scale designed to be sensitive to change.Br J Psychiatry. 1979;134:382-389.
17. Riedel M,Möller HJ,Obermeier M,et al.Response and remission criteria in major depression - a validation of current practice.J Psychiatr Res. 2010;44:1063-1068.
18. Cohen JStatistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.Hillsdale, NJ: Lawrence Erlbaum Associates; 1988:.
19. Risch N,Herrell R,Lehner T,et al.Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis.JAMA. 2009;301:2462-2471.
20. Arias T,Beaumont J,López B,et al.Association of the peroxisome proliferator-activated receptor α gene L162V polymorphism with stage C heart failure.J Hypertens. 2011;29:876-883.
21. Arias A,Freire R,De La Roche JP,et al.Identification, inheritance, and variation of microsatellite markers in the black scallop Mimachlamys varia.Biochem Genet. 2011;49:139-152.
22. Serretti A,Gibiino S,Olgiati P.Pharmacogenetics of antidepressants and mood stabilizers.Handb Clin Neurol. 2012;106:715-744.
23. Abou Jamra R,Becker T,Georgi A,et al.Genetic variation of the FAT gene at 4q35 is associated with bipolar affective disorder.Mol Psychiatry. 2008;13:277-284.
24. Shi J,Badner JA,Gershon ES,et al.Allelic association of G72/G30 with schizophrenia and bipolar disorder: a comprehensive meta-analysis.Schizophr Res. 2008;98:89-97.
25. Zimmerman M,Chelminski I,McDermut W.Major depressive disorder and axis I diagnostic comorbidity.J Clin Psychiatry. 2002;63:187-193.
26. Zimmerman M,Mattia JI,Posternak MA.Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?.Am J Psychiatry. 2002;159:469-473.